US FDA Approves Novo Nordisk's Ozempic to Cut Risk of Diabetic Kidney Disease Progression
(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD), the Danish drugmaker said on Tuesday.
Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...
Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.
Amy Schumer admitted that she took Ozempic almost three years ago to lose weight after giving birth to her son.
An inquest in Cork has been told that a 66-year old woman died from "profound vomiting" brought on by the drug Ozempic, which ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
A gut microbe has been identified that mimics the effects of Ozempic to mitigate diabetes and obesity. Here's how to take ...
Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.
Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback